Evoke Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 194.1%.

Top 24 shareholders own 44.03% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
10.3%	Nantahala Capital Management, LLC	84,686	US$491.2k	50.6%	0.04%
8.74%	Laurence Lytton	71,610	US$415.3k	0%	no data
8.39%	Bleichroeder LP	68,749	US$398.7k	0%	0.1%
7.48%	Lytton-Kambara Foundation, Endowment Arm	61,274	US$355.4k	0%	36.63%
7.04%	Altium Capital Management LP	57,703	US$334.7k	-4.48%	0.13%
0.51%	Geode Capital Management, LLC	4,140	US$24.0k	83.6%	no data
0.3%	The Vanguard Group, Inc.	2,487	US$14.4k	0%	no data
0.29%	David Gonyer	2,360	US$13.7k	0%	no data
0.28%	Cam Garner	2,331	US$13.5k	0%	no data
0.2%	Matthew D'Onofrio	1,653	US$9.6k	0%	no data
0.12%	Citadel Advisors LLC	992	US$5.8k	0%	no data
0.11%	State Street Global Advisors, Inc.	888	US$5.2k	0%	no data
0.076%	Tower Research Capital Europe Limited	623	US$3.6k	0.97%	no data
0.051%	Mark Kowieski	417	US$2.4k	0%	no data
0.044%	Marilyn Carlson	360	US$2.1k	0%	no data
0.016%	Malcolm Hill	134	US$777.4	0%	no data
0.015%	BlackRock, Inc.	121	US$701.8	0%	no data
0.011%	UBS Asset Management AG	92	US$533.6	0%	no data
0.0038%	Morgan Stanley, Investment Banking and Brokerage Investments	31	US$179.6	0%	no data
0.0034%	Todd Brady	28	US$162.5	0%	no data
0.0021%	NewEdge Advisors, LLC	17	US$98.8	0%	no data
0.00061%	Strategic Advisers LLC	5	US$29.0	0%	no data
0.00061%	Bank of America Corporation, Asset Management Arm	5	US$29.0	0%	no data
0.00024%	Royal Bank of Canada, Banking & Securities Investments	2	US$11.4	0%	no data